Parallax Volatility Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.05M Sell
85,100
-43,300
-34% -$2.52M 0.01% 573
2025
Q4
$6.93M Buy
128,400
+46,800
+57% +$2.25M 0.01% 579
2025
Q3
$3.68M Sell
81,600
-60,800
-43% -$2.84M 0.01% 760
2025
Q2
$6.59M Buy
142,400
+127,400
+849% +$6.25M 0.01% 552
2025
Q1
$915K Sell
15,000
-438,500
-97% -$25.6M ﹤0.01% 1078
2024
Q4
$25.6M Buy
453,500
+360,200
+386% +$20.1M 0.05% 303
2024
Q3
$4.83M Buy
93,300
+49,800
+114% +$2.34M 0.01% 804
2024
Q2
$1.81M Sell
43,500
-173,000
-80% -$7.74M ﹤0.01% 1075
2024
Q1
$11.7M Sell
216,500
-168,500
-44% -$8.58M 0.03% 471
2023
Q4
$19.8M Buy
385,000
+245,700
+176% +$12.9M 0.04% 393
2023
Q3
$8.08M Sell
139,300
-6,700
-5% -$411K 0.02% 595
2023
Q2
$9.34M Sell
146,000
-468,000
-76% -$31.4M 0.02% 560
2023
Q1
$42.6M Buy
614,000
+67,200
+12% +$4.74M 0.09% 225
2022
Q4
$39.3M Buy
546,800
+110,600
+25% +$8.34M 0.06% 333
2022
Q3
$31M Sell
436,200
-80,400
-16% -$5.83M 0.05% 403
2022
Q2
$39.8M Buy
516,600
+418,100
+424% +$31.8M 0.04% 330
2022
Q1
$7.19M Buy
+98,500
New +$6.61M ﹤0.01% 857
2020
Q4
Sell
-1,351,300
Closed -$81.5M 2478
2020
Q3
$81.5M Buy
1,351,300
+858,300
+174% +$51.7M 0.06% 279
2020
Q2
$29M Sell
493,000
-3,415,800
-87% -$204M 0.03% 403
2020
Q1
$218M Buy
3,908,800
+3,314,100
+557% +$203M 0.28% 51
2019
Q4
$38.2M Buy
594,700
+434,000
+270% +$24.9M 0.04% 258
2019
Q3
$8.15M Sell
160,700
-210,000
-57% -$9.87M 0.01% 657
2019
Q2
$16.8M Sell
370,700
-317,700
-46% -$14.8M 0.02% 403
2019
Q1
$32.8M Sell
688,400
-90,300
-12% -$4.5M 0.04% 226
2018
Q4
$40.5M Sell
778,700
-99,700
-11% -$5.36M 0.05% 220
2018
Q3
$54.5M Sell
878,400
-161,600
-16% -$9.59M 0.07% 125
2018
Q2
$57.6M Buy
1,040,000
+945,000
+995% +$51M 0.08% 105
2018
Q1
$6.01M Sell
95,000
-45,000
-32% -$2.89M 0.01% 471
2017
Q4
$8.58M Buy
+140,000
New +$8.76M 0.01% 455
2017
Q1
Sell
-27,000
Closed -$1.58M 3570
2016
Q4
$1.58M Hold
27,000
﹤0.01% 1060
2016
Q3
$1.46M Sell
27,000
-1,600
-6% -$103K ﹤0.01% 1110
2016
Q2
$2.1M Sell
28,600
-11,200
-28% -$791K ﹤0.01% 911
2016
Q1
$2.54M Sell
39,800
-64,600
-62% -$4.07M 0.01% 823
2015
Q4
$7.18M Sell
104,400
-63,300
-38% -$4.18M 0.01% 554
2015
Q3
$9.93M Buy
167,700
+88,000
+110% +$5.58M 0.02% 452
2015
Q2
$5.3M Sell
79,700
-130,500
-62% -$8.6M 0.01% 695
2015
Q1
$13.6M Sell
210,200
-207,700
-50% -$13M 0.03% 389
2014
Q4
$24.7M Buy
417,900
+15,000
+4% +$846K 0.07% 258
2014
Q3
$20.6M Buy
402,900
+120,200
+43% +$6M 0.07% 254
2014
Q2
$13.7M Buy
282,700
+35,600
+14% +$1.75M 0.06% 250
2014
Q1
$12.8M Sell
247,100
-498,700
-67% -$26.5M 0.08% 209
2013
Q4
$39.6M Buy
745,800
+297,000
+66% +$15.1M 0.19% 111
2013
Q3
$20.8M Sell
448,800
-11,300
-2% -$496K 0.11% 164
2013
Q2
$20.6M Buy
+460,100
New +$20M 0.1% 164

Other funds holding BMY

Parallax Volatility Advisers's BMY Position: Q1 2026 in Review

Parallax Volatility Advisers opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 30,431 shares worth $1.81M. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings. This is a return to the name: Parallax Volatility Advisers previously reported a position in BMY as recently as Q2 2025.

Parallax Volatility Advisers first reported a position in BMY in Q2 2013 and has held it in 27 quarters since. The position peaked at $95M in Q1 2020. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Parallax Volatility Advisers held 30,431 shares of Bristol-Myers Squibb worth $1.81M as of Q1 2026.
  • Bristol-Myers Squibb was a new Parallax Volatility Advisers position in Q1 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #813 holding.
  • Parallax Volatility Advisers first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 27 quarters since.
  • Parallax Volatility Advisers's Bristol-Myers Squibb position peaked at $95M in Q1 2020.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.